Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Links shared publicly online about this topic.

1,732
total visits

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

View full resource at news-medical.net

Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Alimta